4K Broadcasting

Breakthroughs in HER2-Targeted ADCs for Treating Brain Metastases in Lung Cancer: Clinical Progress from DS-8201 to SHR-A1811

by
Breakthroughs in HER2-Targeted ADCs for Treating Brain Metastases in Lung Cancer: Clinical Progress from DS-8201 to SHR-A1811

Abstract: Brain metastases (BMs) from lung cancer are one of the major factors contributing to poor prognosis in patients with non-small cell lung cancer (NSCLC). In recent years, antibody-drug conjugates (ADCs) have emerged as a new hope for treating HER2-mutant NSCLC due to their precise targeting and potent anti-tumor activity. This article focuses on the … Read more

From Single Target to Multidimensional Breakthrough: The New Landscape and Strategic Evolution of Next-Generation ADC Drug Bioanalysis

by
From Single Target to Multidimensional Breakthrough: The New Landscape and Strategic Evolution of Next-Generation ADC Drug Bioanalysis

With the breakthrough progress of novel structures such as bispecific ADCs and dual payload ADCs, ADC drugs have transitioned from “single-target precision strikes” to a new era of “multidimensional collaborative operations.” These innovative designs greatly expand therapeutic potential but also make their molecular structures, mechanisms of action, and in vivo fates unprecedentedly complex. In this … Read more

Where to Bet on the Next Generation of ADCs?

by
Where to Bet on the Next Generation of ADCs?

Wu Ni | Author You Yi | Editor In October, Hansoh Pharmaceutical licensed the overseas rights of its self-developed ADC drug targeting CDH17 to Roche. This gastrointestinal tumor target was also a hot topic at this year’s AACR conference, where over ten related ADC drugs were showcased, with nine from Chinese pharmaceutical companies. Industry insiders … Read more

Key Considerations for ADC Segmented Production

by
Key Considerations for ADC Segmented Production

Thank you for your continued support. Let’s start learning now To do things well, one must do good things, and to do good things, one must do them well. Q6661 What are the main risks in ADC segmented production?The main risks in ADC segmented production are concentrated in the transportation and handover of intermediate products. … Read more

Sutro R&D Day: Next Generation ADC

by
Sutro R&D Day: Next Generation ADC

On November 12, Sutro held its R&D Day event. With the complete termination of the original pillar product FRα, Sutro’s situation is not optimistic. The focus of this R&D Day event remains on ADCs.Related Reading: Sutro 25H1: ROR1 is returned, continuing to push the dual payload platformSutro pointed out that its platform expands the therapeutic … Read more

Essential for Engineers! How Can 10-bit ADCs Achieve High Precision? Tips for Adaptive Resolution

by
Essential for Engineers! How Can 10-bit ADCs Achieve High Precision? Tips for Adaptive Resolution

For electronic engineers, extracting maximum performance from circuits is crucial, especially for Analog-to-Digital Converters (ADC). Among these, resolution is one of the key indicators for optimal ADC performance. However, once the ADC and its reference voltage are determined, the highest resolution achievable in a single sample seems to be a fixed limit. For example, with … Read more

From a $1.8 Billion ADC Trio to a Unicycle: Rina-S Faces Major Challenges in 2024

by
From a $1.8 Billion ADC Trio to a Unicycle: Rina-S Faces Major Challenges in 2024

Recently, Genmab quietly removed another ADC—GEN1160 (targeting CD70) from its clinical list, citing only one reason: “slow enrollment of participants.” This follows the announcement in September to abandon the PTK7 project GEN1107, marking the second “vessel” lost from the same $1.8 billion acquisition. As of now, the three clinical “tickets” sold to Genmab by ProfoundBio … Read more

Strategic Planning in ADC Development: How to Innovate in the Crowded HER2 ADC Space?

by
Strategic Planning in ADC Development: How to Innovate in the Crowded HER2 ADC Space?

The emergence of T-DXd represents a significant breakthrough in the treatment of HER2-positive and HER2-low expressing breast cancer. However, like any effective anti-cancer therapy, acquired resistance remains a major challenge affecting the long-term benefits for patients. Since the launch of Trastuzumab emtansine in 2013, five HER2 ADCs have been approved:Table 1: Approved HER ADCsAs clinical … Read more

Overview of Six Major Breast Cancer ADCs Launched in China

by
Overview of Six Major Breast Cancer ADCs Launched in China

Introduction Breast cancer is one of the most common malignant tumors among women worldwide and is also a leading cause of cancer-related deaths. According to the data released in the “2022 Global Cancer Statistics Report”, there were approximately 20 million new cancer cases globally, with women accounting for 9.7 million, and breast cancer accounting for … Read more